Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a company specializing in treatments for rare diseases, has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, set to take place in San Francisco, CA, on January 14, 2026, at 11:15 a.m. PT. The event will feature a presentation and a live question-and-answer session, accessible via the Investors section of Mirum's corporate website.

Founded to address unmet medical needs in rare diseases, Mirum boasts a robust portfolio of approved products and an extensive pipeline of investigational therapies aimed at conditions often overlooked in the healthcare landscape. The company’s commercial offerings include LIVMARLI® (maralixibat), designed for patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Other products include CHOLBAM® (cholic acid) targeting bile-acid synthesis disorders, and CTEXLI® (chenodiol), aimed at treating cerebrotendinous xanthomatosis (CTX).

In addition to its marketed products, Mirum’s clinical pipeline shows promise with therapies like volixibat, an IBAT inhibitor in advanced stages of development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Another candidate, MRM-3379, is a PDE4D inhibitor evaluated for Fragile X syndrome (FXS). The company is committed to bringing impactful medicines to market through strategic development initiatives, disciplined execution, and collaborations within the rare disease community.

For further information, interested parties can visit Mirum's official website or follow the company's updates on social media platforms, including Facebook, LinkedIn, Instagram, and X (formerly Twitter). For investor-related inquiries, Andrew McKibben is the point of contact via email. Media inquiries can be directed to Meredith Kiernan.

As Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) prepares for its presentation at the 44th Annual J.P. Morgan Healthcare Conference, investors should take a focused look at the company's strategic positioning within the rare disease sector. Mirum's commitment to addressing unmet medical needs, evidenced by its robust product portfolio and pipeline, sets a strong foundation for future growth.

Mirum's commercial offerings, including LIVMARLI® for Alagille syndrome and progressive familial intrahepatic cholestasis, demonstrate its success in niche markets that have historically lacked effective therapies. These approved products potentially provide a steady revenue stream and underscore the company’s expertise in rare disease management.

Investors should also consider Mirum's clinical pipeline, particularly volixibat, an IBAT inhibitor targeting primary sclerosing cholangitis and primary biliary cholangitis, and MRM-3379 for Fragile X syndrome. With volixibat in late-stage development, successful outcomes in clinical trials could significantly enhance the company's valuation and plant Mirum as a leader in these targeted therapeutic areas.

Moreover, during the J.P. Morgan conference, anticipated discussions around ongoing clinical studies and potential partnerships will be critical for gauging the company’s trajectory. Collaborative efforts within the rare disease community not only enhance Mirum’s visibility but also facilitate access to innovative research and resources, thereby speeding up the development of new treatments.

In summary, investors looking at Mirum Pharmaceuticals should remain attuned to upcoming data releases, clinical trial progress, and partnership announcements following the conference. Overall, with its unique focus and strategic initiatives, MIRM presents a compelling case for inclusion in a diversified healthcare portfolio, particularly for those interested in rare diseases with high growth potential.